ABBOTT LABORATORIES (ABT)       107.58  +2.58 (+2.46%)

107.58  +2.58 (+2.46%)

US0028241000 - Common Stock - After market: 107.4 -0.18 (-0.17%)


Fundamental Rating

6

Overall ABT gets a fundamental rating of 6 out of 10. We evaluated ABT against 221 industry peers in the Health Care Equipment & Supplies industry. ABT has a great profitability rating, but there are some minor concerns on its financial health. ABT is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

9

ABT has a Return On Assets of 10.84%. This is amongst the best returns in the industry. The industry average is -18.33%. ABT outperforms 92% of its industry peers.
ABT has a Return On Equity of 22.11%. This is better than the industry average of 10.59%.

ABT has a Profit Margin of 17.52%. This is amongst the best returns in the industry. The industry average is -28.67%. ABT outperforms 91% of its industry peers.
The Piotroski-F score of ABT is 9.00. This is a very strong score and indicates great health and profitability for ABT.
VS Industry

ROA (10.84%) VS Industry: 92% outperformed.

-771.54
117.69

ROE (22.11%) VS Industry: 80% outperformed.

0.69
140.68

Profit Margin (17.52%) VS Industry: 91% outperformed.

-142,068.42
1,450.19

Valuation

Valuation Rating

3

Compared to an average industry Price/Earning Ratio of 23.64, ABT is valued a bit cheaper than its industry peers.
The Price/Earnings Ratio is 19.11, which indicates a rather expensive current valuation of ABT.
With a Forward Price/Earnings Ratio of 23.01, ABT is valued rather expensively.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

When comparing the current price to the book value of ABT, we can conclude it is valued correctly. It is trading at 5.26 times its book value.
Compared to an average industry Enterprise Value to EBITDA ratio of 12.19, ABT is valued in line with its industry peers.
Compared to an average industry price book ratio of 2.66, ABT is valued more expensive than its industry peers.
VS Industry

Price/Earnings (19.11) VS Industry: 63% outperformed.

1,904.64
0.04

Price/Book (5.26) VS Industry: 29% outperformed.

1,042.45
0.08

Enterprise Value/ EBITDA (14.63) VS Industry: 43% outperformed.

4,786.74
0.00

Growth

Growth Rating

3

ABT shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.82% yearly.
The Revenue has been growing by 15.61% on average over the past 5 years. This is quite good.
The Earnings Per Share has been growing slightly by 5.43% over the past year.
The Earnings Per Share is expected to grow by 0.04% on average over the next 5 years.

ABT shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
The Revenue is expected to decrease by -1.32% on average over the next 5 years.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS18.82% 21.85% 5.43% -2.03% -5.26% -0.29% 0.04%
Revenue15.61% 12.1% 6.43% 2.19% -3.56% -0.66% -1.32%

Health

Health Rating

6

ABT has an Altman-Z score of 4.88. This indicates that ABT is financially healthy and little risk of bankruptcy at the moment.
ABT is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.80.
The Piotroski-F score of ABT is 9.00. This is a very strong score and indicates great health and profitability for ABT.
ABT has a Current Ratio of 1.86. This is a normal value and indicates that ABT is financially healthy and should not expect problems in meeting its short term obligations.

A Quick Ratio of 1.43 indicates that ABT should not have too much problems paying its short term obligations.
When comparing the Current Ratio of ABT to the average industry Current Ratio of 3.66, ABT is less able to pay its short term obligations than its industry peers. 82% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 2.92, ABT is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.09, ABT is more dependent on financing than its industry peers.
VS Industry

Debt/Equity (0.43) VS Industry: 27% outperformed.

336.87
0.00

Quick Ratio (1.43) VS Industry: 24% outperformed.

0.06
31.22

Current Ratio (1.86) VS Industry: 18% outperformed.

0.13
31.22

Altman-Z (4.88) VS Industry: 73% outperformed.

-105.06
70.07

Dividend

Dividend Rating

5

Compared to an average industry Dividend Yield of 1.24, ABT pays a bit more dividend than its industry peers.
On average, the dividend of ABT grows each year by 17.13%, which is quite nice.
ABT has paid a dividend for at least 10 years, which is a reliable track record.
With a Yearly Dividend Yield of 1.81%, ABT has a reasonable but not impressive dividend return.

41.63% of the earnings are spent on dividend by ABT. This is a bit on the high side, but may be sustainable.
ABT's Dividend Yield is slightly below the S&P500 average, which is at 2.47.
ABT's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
VS Industry

Dividend Yield (1.81%) VS Industry: 72% outperformed.

0.02
6.19
ABT Daily chart

ABBOTT LABORATORIES107.58

NYSE:ABT (11/30/2022, 7:17:20 PM)+2.58 (+2.46%)

After market: 107.4 -0.18 (-0.17%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Equipment & Supplies
Earnings (Last) 10-19 2022-10-19/bmo Earnings (Next) 01-24 2023-01-24
Ins Owners 0.7% Inst Owners 175.76%
Market Cap 187.57B Analysts 78
Valuation
PE 19.11 Fwd PE 23.01
PEG (NY) N/A PEG (5Y) 1.02
P/S 4.17 P/B 5.26
EV/EBITDA 14.63
Dividend
Dividend Yield 1.81% Dividend Growth 17.13%
DP 41.63% Ex-Date 10-13 2022-10-13 (0.47)
Growth
EPS 1Y 5.43% EPS 3Y 21.85%
EPS 5Y 18.82% EPS growth Q2Q -17.86%
EPS Next Y -2.03% EPS Next 2Y -5.26%
EPS Next 3Y -0.29% EPS Next 5Y 0.04%
Revenue growth 1Y 6.43% Revenue growth 3Y 12.1%
Revenue growth 5Y 15.61% Revenue growth Q2Q -4.74%
Revenue Next Year 2.19% Revenue Next 2Y -3.56%
Revenue Next 3Y -0.66% Revenue Next 5Y -1.32%
Health
Current Ratio 1.86 Quick Ratio 1.43
Altman-Z 4.88 F-Score 9
Debt/Equity 0.43 WACC 9.07%
ROIC/WACC 5.7
Profitability
ROA 10.84% ROE 22.11%
ROICexgc 51.68% ROIC 14.26%
PM 17.52% OM 21.31%
Asset Turnover 0.62

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA